10th January 2020
Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs announces that following the receipt of Notice of Exercise, 1,250,000 ordinary shares of 0.1p each in the Group (the “Warrant Shares”) have now been issued to the warrant holder following exercise at the agreed price of 4p per share. Download News